Business Wire

INDY-AUTONOMOUS-CHALLENG

16.7.2024 16:01:31 CEST | Business Wire | Press release

Share
Indy Autonomous Challenge AI Racecar Presented by Bridgestone Sets Autonomous Hillclimb Record at the Goodwood Festival of Speed

On a busy Sunday afternoon, in front of a global audience of motorsport enthusiasts, The Indy Autonomous Challenge’s (IAC) self-driving AV-24 racecar set the record for the fastest autonomous Hillclimb at the Festival of Speed. The AV-24 is piloted by an AI Driver developed by Team PoliMOVE-MSU (Politecnico di Milano and Michigan State University).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716347266/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The IAC AV-24, a racecar driven by AI, sets autonomous record at the Goodwood Festival of Speed. (Photo: Business Wire)

The AV-24 performed a series of three runs during the iconic festival. The record was broken during their third and final run up the Goodwood Hill where the racecar reached a top speed of 111.2 mph (179 kph) and a finish time of 66.37 secs. The record-setting run can be watched here. The previous record has been held by Roborace since 2019 when their “DevBot 2.0” autonomous car clocked a 66.96 sec time at a top speed of 101.16 mph (162.8 kph).

Goodwood is known for its unforgiving narrow course, lined with hay bells and limited run-off space. Attempting an autonomous hill climb at the Festival of Speed required absolute control of grip and slippage from the AV-24’s Bridgestone racing tires as well as precision mapping and localization in a GPS limited environment resulting in a higher than usual reliance on the AV-24’s Luminar Iris lidars.

The IAC and PoliMOVE-MSU teams worked closely with Bridgestone’s tire engineers to optimize performance ahead of the Hillclimb including traveling to Bridgestone’s European Technical Center and European Proving Grounds in Rome. The team also had the unique chance to explore each step of tire production and test how impactful tire performance is on track.

Paul Mitchell, Chairman and President of the IAC: “For three years, the IAC has been pushing the boundaries of high-speed autonomy and setting new records along the way. The Goodwood Hillclimb is a historic backdrop with huge crowds and a global audience that is now aware of the potential of self-driving vehicles to be safely deployed on roads in the future.”

Professor Sergio Savaresi, PoliMOVE-MSU Team Principal: “This challenge represents an important milestone for autonomous mobility. This weekend we overcame significant challenges posed by a complicated track and temperamental weather patterns. Thanks to the exceptional work and skills implemented by our engineering team and tire performance ensured by our Bridgestone racing tires, we made history by showing the public that safe and high-speed vehicular autonomy is possible even in adverse conditions. Our record at the Goodwood Festival of Speed will inspire confidence in future autonomous driving applications.”

Sara Correa, Chief Marketing Officer for Bridgestone in the Americas, Europe, Middle East and Africa (EMEA) added, “Bridgestone is proud to support the PoliMOVE-MSU team in this incredible achievement at the Goodwood Festival of Speed 2024. We are committed to partnering with the IAC and its inspiring student engineers to continue testing and improving autonomous technologies in record-setting runs like this and beyond. Motorsports are part of Bridgestone’s DNA, always have been and always will be. And what really matters is that we take the learnings from experiences like this and apply them to the sustainable mobility solutions we develop for society and our customers.”

Visuals and footage including of the IAC’s Autonomous Hillclimb can be found here.

About the IAC: The Indy Autonomous Challenge (IAC) is a non-profit corporation based in Indianapolis, Indiana (USA) that organizes racing competitions among 10 university-affiliated teams representing 18 universities from around the world. Teams program AI drivers to pilot fully autonomous racecars and compete in a series of history-making events at iconic tracks. The IAC is working to establish a hub for performance automation in the state and is harnessing the power of innovative competitions to attract the best and the brightest minds from around the globe to further state-of-the-art technology in the safety and performance of autonomous vehicles. The IAC started as a $1 million prize competition with 31 university teams signing up to compete more than three years ago, representing top engineering and technology programs from 15 U.S. states and 11 countries. Follow the IAC @IndyAChallenge on LinkedIn, Twitter, Instagram, Facebook, & YouTube.

About Bridgestone: Bridgestone is a global leader in tires and rubber building on its expertise to provide solutions for safe and sustainable mobility. Headquartered in Tokyo, the company employs approximately 130,000 people globally, conducting business in more than 150 countries and territories worldwide. Bridgestone offers a diverse product portfolio of premium tires and advanced solutions backed by innovative technologies, improving the way people around the world move, live, work and play.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240716347266/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye